Every Monday our authors provide a round-up of some of the most recently published peer reviewed articles from the field. We don’t cover everything, or even what’s most important – just a few papers that have interested the author. Visit our Resources page for links to more journals or follow the HealthEconBot. If you’d like to write one of our weekly journal round-ups, get in touch.
Core items for a standardized resource use measure (ISRUM): expert Delphi consensus survey. Value in Health Published 1st September 2017
Trial-based collection of resource use data, for the purpose of economic evaluation, is wild. Lots of studies use bespoke questionnaires. Some use off-the-shelf measures, but many of these are altered to suit the context. Validity rarely gets a mention. Some of you may already be aware of this research; I’m sure I’m not the only one here who participated. The aim of the study is to establish a core set of resource use items that should be included in all studies to aid comparability, consistency and validity. The researchers identified a long list of 60 candidate items for inclusion, through a review of 59 resource use instruments. An NHS and personal social services perspective was adopted, and any similar items were merged. This list was constructed into a Delphi survey. Members of the HESG mailing list – as well as 111 other identified experts – were invited to complete the survey, for which there were two rounds. The first round asked participants to rate the importance of including each item in the core set, using a scale from 1 (not important) to 9 (very important). Participants were then asked to select their ‘top 10’. Items survived round 1 if they scored at least 7 with more than 50% of respondents, and less than 3 by no more than 15%, either overall or within two or more participant subgroups. In round 2, participants were presented with the results of round 1 and asked to re-rate 34 remaining items. There was a sample of 45 usable responses in round 1 and 42 in round 2. Comments could also be provided, which were subsequently subject to content analysis. After all was said and done, a meeting was held for final item selection based on the findings, to which some survey participants were invited but only one attended (sorry I couldn’t make it). The final 10 items were: i) hospital admissions, ii) length of stay, iii) outpatient appointments, iv) A&E visits, v) A&E admissions, vi) number of appointments in the community, vii) type of appointments in the community, viii) number of home visits, ix) type of home visits and x) name of medication. The measure isn’t ready to use just yet. There is still research to be conducted to identify the ideal wording for each item. But it looks promising. Hopefully, this work will trigger a whole stream of research to develop bolt-ons in specific contexts for a modular system of resource use measurement. I also think that this work should form the basis of alignment between costing and resource use measurement. Resource use is often collected in a way that is very difficult to ‘map’ onto costs or prices. I’m sure the good folk at the PSSRU are paying attention to this work, and I hope they might help us all out by estimating unit costs for each of the core items (as well as any bolt-ons, once they’re developed). There’s some interesting discussion in the paper about the parallels between this work and the development of core outcome sets. Maybe analysis of resource use can be as interesting as the analysis of quality of life outcomes.
A call for open-source cost-effectiveness analysis. Annals of Internal Medicine [PubMed] Published 29th August 2017
Yes, this paper is behind a paywall. Yes, it is worth pointing out this irony over and over again until we all start practising what we preach. We’re all guilty; we all need to keep on keeping on at each other. Now, on to the content. The authors argue in favour of making cost-effectiveness analysis (and model-based economic evaluation in particular) open to scrutiny. The key argument is that there is value in transparency, and analogies are drawn with clinical trial reporting and epidemiological studies. This potential additional value is thought to derive from i) easy updating of models with new data and ii) less duplication of efforts. The main challenges are thought to be the need for new infrastructure – technical and regulatory – and preservation of intellectual property. Recently, I discussed similar issues in a call for a model registry. I’m clearly in favour of cost-effectiveness analyses being ‘open source’. My only gripe is that the authors aren’t the first to suggest this, and should have done some homework before publishing this call. Nevertheless, it is good to see this issue being raised in a journal such as Annals of Internal Medicine, which could be an indication that the tide is turning.
Differential item functioning in quality of life measurement: an analysis using anchoring vignettes. Social Science & Medicine [PubMed] [RePEc] Published 26th August 2017
Differential item functioning (DIF) occurs when different groups of people have different interpretations of response categories. For example, in response to an EQ-5D questionnaire, the way that two groups of people understand ‘slight problems in walking about’ might not be the same. If that were the case, the groups wouldn’t be truly comparable. That’s a big problem for resource allocation decisions, which rely on trade-offs between different groups of people. This study uses anchoring vignettes to test for DIF, whereby respondents are asked to rate their own health alongside some health descriptions for hypothetical individuals. The researchers conducted 2 online surveys, which together recruited a representative sample of 4,300 Australians. Respondents completed the EQ-5D-5L, some vignettes, some other health outcome measures and a bunch of sociodemographic questions. The analysis uses an ordered probit model to predict responses to the EQ-5D dimensions, with the vignettes used to identify the model’s thresholds. This is estimated for each dimension of the EQ-5D-5L, in the hope that the model can produce coefficients that facilitate ‘correction’ for DIF. But this isn’t a guaranteed approach to identifying the effect of DIF. Two important assumptions are inherent; first, that individuals rate the hypothetical vignette states on the same latent scale as they rate their own health (AKA response consistency) and, second, that everyone values the vignettes on an equivalent latent scale (AKA vignette equivalence). Only if these assumptions hold can anchoring vignettes be used to adjust for DIF and make different groups comparable. The researchers dedicate a lot of effort to testing these assumptions. To test response consistency, separate (condition-specific) measures are used to assess each domain of the EQ-5D. The findings suggest that responses are consistent. Vignette equivalence is assessed by the significance of individual characteristics in determining vignette values. In this study, the vignette equivalence assumption didn’t hold, which prevents the authors from making generalisable conclusions. However, the researchers looked at whether the assumptions were satisfied in particular age groups. For 55-65 year olds (n=914), they did, for all dimensions except anxiety/depression. That might be because older people are better at understanding health problems, having had more experience of them. So the authors can tell us about DIF in this older group. Having corrected for DIF, the mean health state value in this group increases from 0.729 to 0.806. Various characteristics explain the heterogeneous response behaviour. After correcting for DIF, the difference in EQ-5D index values between high and low education groups increased from 0.049 to 0.095. The difference between employed and unemployed respondents increased from 0.077 to 0.256. In some cases, the rankings changed. The difference between those divorced or widowed and those never married increased from -0.028 to 0.060. The findings hint at a trade-off between giving personalised vignettes to facilitate response consistency and generalisable vignettes to facilitate vignette equivalence. It may be that DIF can only be assessed within particular groups (such as the older sample in this study). But then, if that’s the case, what hope is there for correcting DIF in high-level resource allocation decisions? Clearly, DIF in the EQ-5D could be a big problem. Accounting for it could flip resource allocation decisions. But this study shows that there isn’t an easy answer.
How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: a conceptual framework. Health Economics [PubMed] Published 22nd August 2017
The starting point for this paper is that, when it comes to reimbursement decisions, the more time and money spent on the appraisal process, the more precise the cost-effectiveness estimates are likely to be. So the question is, how much should be committed to the appraisal process in the way of resources? The authors set up a framework in which to consider a variety of alternatively defined appraisal processes, how these might maximise population health and which factors are key drivers in this. The appraisal process is conceptualised as a diagnostic tool to identify which technologies are cost-effective (true positives) and which aren’t (true negatives). The framework builds on the fact that manufacturers can present a claimed ICER that makes their technology more attractive, but that the true ICER can never be known with certainty. As a diagnostic test, there are four possible outcomes: true positive, false positive, true negative, or false negative. Each outcome is associated with an expected payoff in terms of population health and producer surplus. Payoffs depend on the accuracy of the appraisal process (sensitivity and specificity), incremental net benefit per patient, disease incidence, time of relevance for an approval, the cost of the process and the price of the technology. The accuracy of the process can be affected by altering the time and resources dedicated to it or by adjusting the definition of cost-effectiveness in terms of the acceptable level of uncertainty around the ICER. So, what determines an optimal level of accuracy in the appraisal process, assuming that producers’ price setting is exogenous? Generally, the process should have greater sensitivity (at the expense of specificity) when there is more to gain: when a greater proportion of technologies are cost-effective or when the population or time of relevance is greater. There is no fixed optimum for all situations. If we relax the assumption of exogenous pricing decisions, and allow pricing to be partly determined by the appraisal process, we can see that a more accurate process incentivises cost-effective price setting. The authors also consider the possibility of there being multiple stages of appraisal, with appeals, re-submissions and price agreements. The take-home message is that the appraisal process should be re-defined over time and with respect to the range of technologies being assessed, or even an individualised process for each technology in each setting. At least, it seems clear that technologies with exceptional characteristics (with respect to their potential impact on population health), should be given a bespoke appraisal. NICE is already onto these ideas – they recently introduced a fast track process for technologies with a claimed ICER below £10,000 and now give extra attention to technologies with major budget impact.
Credits
